Author Archives: Pascal Winnen

Vedanta Biosciences Closes Extended $45.5 Million Series C Financing

  May 13, 2019   $18.5 million in extension funding will support clinical pipeline of microbiome-derived product candidates CAMBRIDGE, Mass., May 13, 2019— Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C […]

Polyphor temporarily halts enrollment in the Phase III studies of murepavadin for the treatment of patients with nosocomial pneumonia

  Allschwil, Switzerland, May 9, 2019 Polyphor temporarily halts enrollment in the Phase III studies of murepavadin for the treatment of patients with nosocomial pneumonia Polyphor (SIX: POLN) today announced the decision to temporarily halt enrollment for the pivotal Phase III trials PRISM-MDR and PRISM-UDR evaluating murepavadin in patients with nosocomial pneumonia due to higher […]

Pfizer Acquires Swiss Clinical-Stage Biotech Therachon

Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on […]

Venture Leaders Life Sciences Boston For Swiss startups ready to take over the world

For the past 18 years, Swiss National Startup Teams have traveled to Boston, New York, Beijing, Shanghai, Shenzhen or Hong Kong to dive into the exciting entrepreneurial scene of such high level entrepreneurial hubs, helping more than 300 entrepreneurs to build their vision and achieve success. Several of them belong to the best Swiss startups today, […]

Improved IVF Screening and Ultra-fast Aerodynamic Simulation Software Startups win CHF 130,000

Promising news from our portfolio company Annaida Technologies: Improved IVF Screening (Lausanne, EPF spin-off) About 1 in 10 couples in developed countries use in-vitro fertilization when trying to conceive and Europe’s clinics perform 660,000 IVF cycles every year. Globally IVF will be a $20 billion industry by 2020, with patients spending over $1 billion on […]

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO™ (fosfomycin) for injection

April 30, 2019 at 8:16 PM EDT Issues related to facility inspections and manufacturing deficiencies at one contract manufacturer Conference call and webcast tomorrow at 8:00 a.m. EDT   DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today […]

Who is Switzerland’s Most Promising Startup 2019?

Switzerland is home to hundreds of excellent startups. Every year the TOP 100 Swiss Startup Award showcases the 100 most-innovative and promising Swiss startups. The event, a unique opportunity to discover the best of Swiss innovation, sees a jury of 100 leading investors and experts rank the country’s most-impactful new high-tech companies. You can vote […]

Motif Bio Announces Appointment of Andrew Powell to Board of Directors

  NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB) (“Motif Bio” or the “Company”), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately. Mr. Powell has served as General Counsel at several biotechnology firms, including CollaGenex Pharmaceuticals, ImClone Systems, Cornerstone Therapeutics, InterMune and, […]

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica Ltd. [SIX: BSLN], announced today that they have entered into a research collaboration and license agreement to discover, develop, and commercialize novel antibiotic classes. They will apply Forge’s proprietary BLACKSMITH metalloenzyme chemistry […]